Weltruza requires no loading doses, oral supplementation, or post-injection monitoring, with approval based on the phase 3 SOLARIS trial.
News|Articles|July 6, 2026
Q2 2026 Recap: Nephrology News & Updates
Author(s)Alex Hillenbrand
Here are 7 of the biggest nephrology stories from Q2 of 2026!
Advertisement
Advertisement
The second quarter of 2026 brought continued momentum across nephrology, from landmark regulatory decisions and pivotal phase 3 trial results to advances in precision medicine and evolving approaches to
Related to this article
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Advertisement
Advertisement